281 related articles for article (PubMed ID: 28255023)
21. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
[TBL] [Abstract][Full Text] [Related]
22. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
[TBL] [Abstract][Full Text] [Related]
23. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Gotlib J; Berubé C; Growney JD; Chen CC; George TI; Williams C; Kajiguchi T; Ruan J; Lilleberg SL; Durocher JA; Lichy JH; Wang Y; Cohen PS; Arber DA; Heinrich MC; Neckers L; Galli SJ; Gilliland DG; Coutré SE
Blood; 2005 Oct; 106(8):2865-70. PubMed ID: 15972446
[TBL] [Abstract][Full Text] [Related]
24. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
[TBL] [Abstract][Full Text] [Related]
25. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
26. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.
Noack F; Sotlar K; Notter M; Thiel E; Valent P; Horny HP
Leuk Lymphoma; 2004 Nov; 45(11):2295-302. PubMed ID: 15512820
[TBL] [Abstract][Full Text] [Related]
27. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
28. Midostaurin: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
[TBL] [Abstract][Full Text] [Related]
29. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2023 Jul; 98(7):1097-1116. PubMed ID: 37309222
[TBL] [Abstract][Full Text] [Related]
30. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis.
Aichberger KJ; Sperr WR; Gleixner KV; Kretschmer A; Valent P
Eur J Clin Invest; 2008 Nov; 38(11):869-73. PubMed ID: 19021706
[TBL] [Abstract][Full Text] [Related]
31. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
Horny HP; Sotlar K; Sperr WR; Valent P
J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
[TBL] [Abstract][Full Text] [Related]
32. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
33. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
[TBL] [Abstract][Full Text] [Related]
34. Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in
Naumann N; Rudelius M; Lübke J; Christen D; Bresser J; Sotlar K; Metzgeroth G; Fabarius A; Hofmann WK; Panse J; Horny HP; Cross NCP; Reiter A; Schwaab J
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339343
[TBL] [Abstract][Full Text] [Related]
35. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
36. Mast cell leukemia with prolonged survival on PKC412/midostaurin.
Xu X; Kreisel FH; Frater JL; Hassan A
Int J Clin Exp Pathol; 2014; 7(6):3439-43. PubMed ID: 25031773
[TBL] [Abstract][Full Text] [Related]
37. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
38. From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia.
Decker J; Meyer S; Latger-Cannard V; Visanica S; Loppinet E; Lesesve JF; Bénet B
Ann Biol Clin (Paris); 2017 Dec; 75(6):689-694. PubMed ID: 29043985
[TBL] [Abstract][Full Text] [Related]
39. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
40. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.
Pardanani A; Shah S; Mannelli F; Elala YC; Guglielmelli P; Lasho TL; Patnaik MM; Gangat N; Ketterling RP; Reichard KK; Hanson CA; Vannucchi AM; Tefferi A
Blood Adv; 2018 Nov; 2(21):2964-2972. PubMed ID: 30413432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
